KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18) (KONCERT)
Sponsor: ANRS, Emerging Infectious Diseases
Listed as NCT01196195, this PHASE2/PHASE3 trial focuses on Antiretroviral Therapy in HIV-1 Infected Children and remains completed. Sponsored by ANRS, Emerging Infectious Diseases, it has been updated 8 times since 2010, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE2_PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ANRS, Emerging Infectious Diseases
- Medical Research Council
- PENTA Foundation
For direct contact, visit the study record on ClinicalTrials.gov .